NCT06107608 Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inhibitors
| NCT ID | NCT06107608 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jules Bordet Institute |
| Condition | Non Small Cell Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 58 participants |
| Start Date | 2023-06-13 |
| Primary Completion | 2027-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 58 participants in total. It began in 2023-06-13 with a primary completion date of 2027-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Evaluation of the relation between baseline fibroblast activation protein (FAP) expression based on Ga-FAPI uptake with patient outcome among NSCLC patients receiving immunotherapy for recurrent/metastatic disease.
Eligibility Criteria
Inclusion Criteria: * Age above 18 years. * Pathologically- proven non-small-cell lung cancer (NSCLC). * Proposed for treatment with anti-PD-(L)1 alone or in combination with chemotherapy and/or anti-CTLA4 in the advanced setting. * ECOG Performance status ≤2. * Patient's written informed consent obtained prior to any study procedure. Exclusion Criteria: * Surgery and/or radiotherapy to thoracic region within the last 8 weeks or anti-cancer systemic therapy within the last 2 weeks. * Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and c-ros oncogene (ROS1) mutations. * Pregnant and lactating women * Previous or concurrent malignancy diagnosed within the last 2 years except adequately treated in situ carcinoma of the cervix uteri, localised (T1N0) low grade (Gleason score 6) prostate cancer undergoing active surveillance and basal or squamous cell skin cancer. * Subjects with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.
Frequently Asked Questions
Who can join the NCT06107608 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non Small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06107608 currently recruiting?
Yes, NCT06107608 is actively recruiting participants. Visit ClinicalTrials.gov or contact Jules Bordet Institute to inquire about joining.
Where is the NCT06107608 trial being conducted?
This trial is being conducted at Brussels, Belgium.
Who is sponsoring the NCT06107608 clinical trial?
NCT06107608 is sponsored by Jules Bordet Institute. The trial plans to enroll 58 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.